Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA).

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.